



## **FOR IMMEDIATE RELEASE**

### **Contacts:**

#### **For Ohmx Corporation:**

Dimitra Georganopoulou

Tel: (847) 491-8513

Fax: (847) 491-8510

dimitra@ohmx.com

### **Ohmx Names Dr. Gary Blackburn President and Chief Executive Officer**

**Evanston, IL – April 3, 2006** – Ohmx Corporation, a bioelectronic detection company focused on developing a near-patient analyzer for home monitoring of chronic diseases, is pleased to announce the appointment of Gary Blackburn, Ph.D., as the company's President and CEO.

Dr. Blackburn most recently served as Director of Research and Technology at Motorola Clinical Micro Sensors (CMS). Prior to CMS's acquisition by Motorola in 2000, he served as Vice President of Scientific Affairs at CMS and was instrumental in the development of an electrochemical biosensor device to detect nucleic acids. Dr. Blackburn has contributed significantly in the areas of in biosensors, has authored many publications in the field of detection technologies for chemical sensors and is the inventor on over 30 US and European patents.

"Gary is a proven leader, and his accomplished track record makes him the ideal choice to guide Ohmx's future success. His in-depth knowledge of chemical sensors will help the development of Ohmx's unique technology," said Dr. Thomas Meade, Founder and Chairman of the Board at *Ohmx*.

---

### **About the Company:**

Ohmx is advancing e-Diagnostics by developing a home monitoring device that can quantify clinical biomarkers and other important disease indicators from a finger prick. Ohmx's handheld monitoring device is electric, low-cost, user-friendly, contains advanced communications protocols and can be used as a near-patient analyzer in the convenience of the patient's home. Except for diabetes, there are few consumer devices that can monitor chronic diseases. Ohmx systems address this unmet need by offering a comprehensive platform for tests routinely used for chronic disease monitoring, including cardiac markers, blood gases, electrolytes, metabolites, lipids, cholesterol, glucose, glycosylated serum proteins and hemoglobin. Ohmx Founder & Chairman is Thomas Meade, PhD, who sold his prior company to Motorola for \$300MM; President & CEO is Gary Blackurn, PhD (Boehringer, IGEN), and R&D is headed by Dimitra Georganopoulou, PhD (Inverness, Nanosphere). Ohmx seeks to raise \$10M to fund ongoing product development, manufacturing, and product launch. The Company has raised \$6.6M to date.

*This press release contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.*